Safety and immunogenicity of the anti-cocaine vaccine UFMG-VAC-V4N2 in a non-human primate model

A promising strategy for cocaine addiction treatment is the anti-drug vaccine. These vaccines induce the production of anticocaine antibodies, capable of linking to cocaine, and decrease the passage of cocaine throughout the blood–brain barrier, decreasing drug activity in the brain. Our research gr...

Full description

Saved in:

Bibliographic Details
Published in:	Vaccine Vol. 41; no. 13; pp. 2127 - 2136
Main Authors:	Sabato, Brian, Augusto, Paulo Sérgio de Almeida, Lima Gonçalves Pereira, Raissa, Coutinho Batista Esteves, Felipe, Caligiorne, Sordaini M., Rodrigues Dias Assis, Bruna, Apolo Correia Marcelino, Sóstenes, Pires do Espírito Santo, Larissa, Dias dos Reis, Karine, Da Silva Neto, Leonardo, Goulart, Gisele, de Fátima, Ângelo, Pierezan, Felipe, Toshio Fujiwara, Ricardo, Castro, Maila, Garcia, Frederico
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier Ltd 24-03-2023 Elsevier Limited
Subjects:	Addictions Aluminum Animals Anti-drug vaccine Antibodies Anticocaine vaccine Blood-brain barrier Brain research Calixarenes Cholera Clinical trials Cocaine Cocaine - adverse effects Cocaine use disorder Cocaine-Related Disorders - therapy Drug abuse Drug dosages FDA approval Feeding behavior Immune response Immune system Immunogenicity Immunogenicity, Vaccine International regulations Laboratory animals Medical research Molecular weight Monkeys & apes Narcotics NMR Nuclear magnetic resonance Polyethylene glycol Preclinical study Primates Proteins Safety Safety study Toxicity Vaccines United States > US Safety study Preclinical study Cocaine use disorder Anti-drug vaccine Anticocaine vaccine
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	A promising strategy for cocaine addiction treatment is the anti-drug vaccine. These vaccines induce the production of anticocaine antibodies, capable of linking to cocaine, and decrease the passage of cocaine throughout the blood–brain barrier, decreasing drug activity in the brain. Our research group developed a new vaccine candidate, the UFMG-V4N2, to treat cocaine use disorders (CUD) using an innovative carrier based on calixarenes. This study assessed the safety and immunogenicity of the anti-cocaine vaccine UFMG-VAC-V4N2 in a non-human primate toxicity study using single and multiple vaccine doses. The UFMG-VAC-V4N2 yielded only mild effects in the injection site and did not influence the general health, feeding behavior, or hematological, renal, hepatic, or metabolic parameters in the vaccinated marmosets. The anti-cocaine vaccine UFMG-VAC-V4N2 presented a favorable safety profile and induced the expected immune response in a non-human primate model of Callithrix penicillata. This preclinical UFMG-VAC-V4N2 study responds to the criteria required by international regulatory agencies contributing to future anticocaine clinical trials of this anti-cocaine vaccine.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2023.02.031